OSR Holdings, a significant global healthcare holding company, has recently announced the signing of a memorandum of understanding (MOU) with SillaJen, a biotech firm listed on Kosdaq and renowned for its pipeline of immuno-oncology drug candidates. This MOU signifies a commitment to mutual technological sharing and leveraging clinical development resources, initiating a strategic partnership between the two entities.

重要的全球医疗保健控股公司OSR Holdings最近宣布与SillaJen签署谅解备忘录（MOU），SillaJen是一家在Kosdaq上市的生物技术公司，以其免疫肿瘤候选药物渠道而闻名。这份谅解备忘录意味着双方致力于相互技术共享和利用临床开发资源，在两个实体之间建立战略伙伴关系。

The collaboration aims to explore synergies between their existing platform technologies and novel drug candidates.Established in 2019 in South Korea, OSR Holdings operates on a 'hub-and-spoke' business model, a trend increasingly observed in the biopharmaceutical sector over the past decade. This model allows for centralized management of drug development strategies, clinical plans, and resource allocation by the holding company.

该合作旨在探索其现有平台技术与新型候选药物之间的协同作用。OSR Holdings于2019年在韩国成立，以“中心辐射”的商业模式运营，这是过去十年来生物制药行业日益观察到的趋势。该模型允许控股公司对药物开发策略，临床计划和资源分配进行集中管理。

Subsidiaries under this model focus on advancing new drug assets and technological innovations, enhancing scalability and resource efficiency, particularly during the clinical phases of drug development.OSR Holdings' portfolio includes Vaximm AG, a Swiss entity specializing in immuno-oncology therapeutics; Darnatein, a South Korean company developing osteoarthritis therapeutics; and RMC, a distributor of specialized medical devices.

该模式下的子公司专注于推进新药资产和技术创新，提高可扩展性和资源效率，特别是在药物开发的临床阶段。OSR Holdings的投资组合包括Vaximm AG，这是一家专门从事免疫肿瘤学治疗的瑞士实体；Darnatein是一家开发骨关节炎治疗药物的韩国公司；以及专门医疗器械分销商RMC。

Notably, Vaximm AG has completed Phase 2a clinical trials for glioblastoma, while Darnatein, founded by Dr. Seung-Hyun Choi, is known for its robust platform for cartilage and bone regeneration, with ongoing development of new drugs for various disease indications.SillaJen possesses a diverse pipeline of new drugs, such as the SJ-600 series and BAL0891, and is at the forefront of developing anti-cancer viruses based on its GEEV® platform.

值得注意的是，Vaximm AG已经完成了胶质母细胞瘤的2a期临床试验，而由Seung Hyun Choi博士创立的Darnatein以其强大的软骨和骨再生平台而闻名，并正在开发用于各种疾病适应症的新药。SillaJen拥有多种新药，如SJ-600系列和BAL0891，并且处于基于其GEEV®平台开发抗癌病毒的前沿。

GEEV® is recognized for its immune-evasion capabilities, allowi.

GEEV®以其免疫逃避能力allowi而闻名。